Analysis of the pharmacological effects, indications and clinical application value of Rutrombopag Tablets (Wenda)

Lusutrombopag is an oral thrombopoietin receptor agonist (TPO-RA). By simulating the effect of endogenous thrombopoietin, it stimulates the proliferation and differentiation of bone marrow megakaryocytes, thereby increasing platelet count. This mechanism gives it a significant pharmacological effect in patients with thrombocytopenia, can rapidly increase the number of platelets, and provides a safe hematological basis for invasive procedures or surgeries.

In terms of indications, Rutrombopag Tablets are mainly used in patients with chronic liver disease who have thrombocytopenia (platelet count less than 50,000/μL) and require invasive surgery or procedures. The drug can reduce the risk of bleeding caused by low platelets and provide conditions for patients to successfully complete the surgery. At the same time, it also provides new treatment options for patients who are not suitable for routine transfusion of platelet products, reducing transfusion-related risks and medical costs.

In clinical application, studies have shown that Rutrombopag Tablets can significantly increase platelet levels after short-term medication, and an operable platelet count can usually be reached within 10 to 14 days of medication. Its oral administration form is more convenient than platelet transfusion, and reduces the immune response, infection risk and blood supply restriction problems caused by blood transfusion. Platelet count needs to be monitored during treatment to avoid the risk of thrombosis caused by excessive platelet elevation.

Overall, Lusutrombopag tablets (Lusutrombopag) have important clinical application value in patients with thrombocytopenia. It can not only effectively increase platelet count and reduce the risk of surgical bleeding, but also improve patient experience and treatment compliance through oral administration. In actual use, dose adjustment and follow-up monitoring need to be carried out based on individual condition and blood indicators to ensure equal emphasis on efficacy and safety and achieve the best clinical benefit.

Keyword tags: Rutrombopag, thrombocytopenia,TPOreceptor agonist, chronic liver disease, preparation before surgery

Reference materials:https://www.drugs.com/pro/mulpleta.html